**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Andrew Staron, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA

**Main Body of the Abstract**
Background:  The clinical landscape of transthyretin (ATTR) amyloidosis has changed considerably since the FDA approval of various transthyretin stabilizers and silencers from 2018 onwards. This study describes trends in overall survival (OS) among patients with wild-type (ATTRwt) and variant (ATTRV122I and non-V122I-ATTRv) ATTR amyloidosis.
Methods:  We identified patients diagnosed with ATTR amyloidosis between 1960–2022 from a prospectively maintained database at the Boston University Amyloidosis Center. Patients were grouped according to time period of diagnosis (pre-2000, 2000–2010, 2011–2017, and 2018–2022). Trends in OS were described across ATTR subtypes using Kaplan-Meier analyses and compared using log-rank tests (reference group: 2018–2022).
Results:  Among a total of 1,034 patients with ATTR amyloidosis, 486 (46.7%) had ATTRwt amyloidosis, 137 (13.2%) had ATTRV122I amyloidosis, and 413 (39.8%) had non-V122I-ATTRv amyloidosis. The mean (SD) age in years at diagnosis was 75.6 (7.0), 71.4 (9.0), and 55.5 (12.9) among patients with ATTRwt, ATTRV122I, and non-V122I-ATTRv amyloidosis, respectively. Median OS was shortest (3.3 years) for patients with ATTRV122I amyloidosis and longest (7.7 years) for patients with non-V122I-ATTRv amyloidosis (Figure 1A). Across ATTR subtypes (Figure 1B–D), no diagnosis time period group had a significant difference in OS versus the 2018–2022 group; however, median OS was not reached by the 2018–2022 group in ATTRwt and non-V122I-ATTRv amyloidosis subtypes.
Conclusions:  Longer prospective follow-up is needed to establish the OS impact of changing care standards and emerging treatments for ATTR amyloidosis under real-world conditions. This study is limited by single-referral center bias and potential changing referral patterns over time.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Andrew Staron, Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA

**Main Body of the Abstract**
**Background:**  The clinical landscape of transthyretin (ATTR) amyloidosis has changed considerably since the FDA approval of various transthyretin stabilizers and silencers from 2018 onwards. This study describes trends in overall survival (OS) among patients with wild-type (ATTRwt) and variant (ATTRV122I and non-V122I-ATTRv) ATTR amyloidosis.
**Methods:**  We identified patients diagnosed with ATTR amyloidosis between 1960–2022 from a prospectively maintained database at the Boston University Amyloidosis Center. Patients were grouped according to time period of diagnosis (pre-2000, 2000–2010, 2011–2017, and 2018–2022). Trends in OS were described across ATTR subtypes using Kaplan-Meier analyses and compared using log-rank tests (reference group: 2018–2022).
**Results:**  Among a total of 1,034 patients with ATTR amyloidosis, 486 (46.7%) had ATTRwt amyloidosis, 137 (13.2%) had ATTRV122I amyloidosis, and 413 (39.8%) had non-V122I-ATTRv amyloidosis. The mean (SD) age in years at diagnosis was 75.6 (7.0), 71.4 (9.0), and 55.5 (12.9) among patients with ATTRwt, ATTRV122I, and non-V122I-ATTRv amyloidosis, respectively. Median OS was shortest (3.3 years) for patients with ATTRV122I amyloidosis and longest (7.7 years) for patients with non-V122I-ATTRv amyloidosis (**Figure 1A**). Across ATTR subtypes (**Figure 1B–D**), no diagnosis time period group had a significant difference in OS versus the 2018–2022 group; however, median OS was not reached by the 2018–2022 group in ATTRwt and non-V122I-ATTRv amyloidosis subtypes.
**Conclusions:**  Longer prospective follow-up is needed to establish the OS impact of changing care standards and emerging treatments for ATTR amyloidosis under real-world conditions. This study is limited by single-referral center bias and potential changing referral patterns over time.



A Natural History Study of Transthyretin (ATTR) Amyloidosis: Trends in Overall Survival at a U.S. Referral Center PC65 (#373)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.